-
Nature Metabolism: Qiao Wu's team at Xiamen University revealed a new mechanism by which hepatic stellate cell exohexohrokinase HK1 accelerates the process of liver cancer
Time of Update: 2022-10-12
Hepatocellular carcinoma (HCC) is the most common hepatic malignancy, and more than 80% of clinical liver cancers are developed from liver fibrosis or cirrhosis, suggesting that liver fibrosis can dir
-
Science Advances: First confirmed: epigenetic drug EZH2 inhibitors, which treat bladder cancer by activating the immune system
Time of Update: 2022-10-12
Next, the team used the commercially available EZH2 inhibitor Tazemetostat to treat mice with bladder cancer, and the results showed that tazestat filled the bladders of mice with immune cells.
-
Nat Commun: Injection of synthetic RNA viruses to treat cancer and address the limitations of oncolytic viruses
Time of Update: 2022-10-12
The research team has developed a completely synthetic RNA virus, Synthetic RNA virus, which delivers the RNA viral genome (vRNA) through lipid nanoparticles (LNP), which will solve the limitations of repeated intravenous administration of oncolytic viruses and improve the therapeutic potential of oncolytic viruses.
-
Lancet Oncol: Early targeted therapy bESR1 mutations can have significant outcomes for patients with advanced breast cancer
Time of Update: 2022-10-12
This randomized, open-label Phase 3 clinical trial enrolled patients aged 18 years or older with ECOG performance status of 0-2 points, positive estrogen receptors, and HER2-negative advanced breast cancer to detect the rise of bESR1 mutations during first-line treatment with aromatase inhibitors (letrozole 2.
-
Sci Rep: Worthy of being an "angel in cancer"?
Time of Update: 2022-10-12
86), and a history of thyroid cancer may be a protective factor for liver cancer death in PLC patients (Table 3) .
86), and a history of thyroid cancer may be a protective factor for liver cancer death in PLC patients (Table 3) .
-
The project kick-off meeting of the "Report on the Development of Cancer Science Popularization in China" was successfully held
Time of Update: 2022-10-12
Zhang Fabao, chairman of Mace Medicine, pointed out in his speech that under the leadership of the China Association for Science and Technology and the China Anti-Cancer Association, and under the personal supervision of Director Tian Yantao, the Metz medical team is deeply honored to participate in the "China Oncology Science Popularization Work Development Report" project.
-
European Radiology: Lineage plot of survival prognosis for triple-negative breast cancer
Time of Update: 2022-10-12
The nominative graph model proposed in this study integrates three variables of postoperative adjuvant chemotherapy, axillary lymph node load and malignant acoustic performance, and can be used as an effective imaging tool to predict the survival prognosis of patients with TNBC.
-
15 common malignant pulmonary nodules imaging features are recommended for collection
Time of Update: 2022-10-12
The meaning to be expressed is that the lesion is very close to the pleura, but there is a very small gap, indicating: With the increase in the number of pulmonary nodules found in the examination, their benign and malignant judgments are mainly based on the performance of chest CT images.
-
ESMO 2022: GMO herpes virus provides a deep secondary blow to advanced cancer
Time of Update: 2022-10-12
""The results of our preliminary trials suggest that genetically engineered forms of herpes virus may be a new treatment option for some patients with advanced cancer — including those who haven't responded to other forms of immunotherapy.
-
Hangzhou 41-year-old woman with advanced gallbladder cancer and lost the opportunity for chemotherapy! In fact, there were signs a year ago
Time of Update: 2022-10-12
Advanced gallbladder cancer was detected, and there was no chance of surgical chemotherapyA year ago, I didn't pay attention to the physical examinationMs. Yang is usually in good health.
-
Cancer Cell: Analysis of rare susceptibility mutations in lung cancer based on genome-wide analysis of 6,004 Chinese
Time of Update: 2022-10-12
Research Highlights:We conducted the largest non-small cell lung cancer (NSCLC) whole genome sequencing (WGS) study to date, with 6,004 Chinese individuals and 23,049 individuals genotyped by SNP arrays.
-
MMR: Prof. Yi's team elucidated a new molecular mechanism for the malignant progression of esophageal cancer
Time of Update: 2022-10-12
1186/s40779-022-00412-0 Recently, the team of Professor Hu Yi, director of the Department of Oncology Medicine of the Fifth Medical Center of the PLA General Hospital, and the team of Professor Yan Xiaolong of the Second Affiliated Hospital of the Air Force Military Medical University published a report entitled "Melatonin inhibits ESCC tumor growth by mitigating the HDAC7/β-catenin/c-Myc positive" in the international academic journal Military Medical Research Feedback loop and suppressing the USP10-maintained HDAC7 protein stability" research paper.
-
Cancer Cell: Immunomodulatory mechanisms of tumor-targeted drugs
Time of Update: 2022-10-12
Another DDR-related kinase ATR has been shown to mediate a potent immunosuppressive effect, so ATR inhibitors not only enhance CGAS signaling and subsequent type I interferon response (involving CCL5 and CXCL10), but also enhance antigen presentation of MHCI-class molecules, ultimately favoring tumor infiltration in DC, TAM repolarization in the direction of immune stimulation, and T-cell-dependent anticancer immunity.
-
J Clin Oncol: Order of treatment of choice for BRAFV600 mutant metastatic melanoma
Time of Update: 2022-10-12
Secondary endpoints included 3-year overall survival, objective response rate, duration of response, progression-free survival, and safety.
Secondary endpoints included 3-year overall survival, objective response rate, duration of response, progression-free survival, and safety.
Secondary endpoints included 3-year overall survival, objective response rate, duration of response, progression-free survival, and safety.
-
European Radiology: Noninvasive prediction of colorectal cancer based on CT radiomics features
Time of Update: 2022-10-12
Figure Kaplan-Meier curves in patients with stage I (a), II (b), and III (c) colorectal cancer patients based on MSI status predicted by the line plotThis study constructs and validates a non-invasive radioomics feature model based on conventional clinical CT images for MSI status recognition in CRC patients that can accurately stratify patients with stage II CRC and contribute to clinical decision-making of personalized treatment for CRC patients.
-
Clin Cancer Res: efficacy and safety of atizumab plus bevacizumab in the treatment of advanced mucosal melanoma
Time of Update: 2022-10-12
Progression-free survival rateA total of 43 patients were recruited, including 20 (46.
Progression-free survival rateA total of 43 patients were recruited, including 20 (46.
Progression-free survival rateA total of 43 patients were recruited, including 20 (46.
-
Int J Radiat Oncol Biol Phys: How effective is IVH with or without brachytherapy in patients with very high-risk prostate cancer?
Time of Update: 2022-10-12
Very high-risk (VHR) prostate cancer (PC) is an aggressive subgroup with a high risk of long-range progression in which systematic intensive therapy with abiraterone or docetaxel reduces specific mortality (PCSM) and distal metastases (DM) in men receiving in vitro irradiation radiation therapy (EBRT) and androgen deprivation therapy (ADT).
-
Trastuzumab subcutaneous preparation approved in China for administration in only 2-5 minutes!
Time of Update: 2022-10-12
It is worth mentioning that Roche Pharma China also disclosed that on July 27 this year, the domestic marketing application of Roche pertuzumab trastuzumab injection (subcutaneous injection) was accepted, which is a fixed-dose combination of subcutaneous preparations (trade name Phesgo®), which has previously been approved in the United States, the European Union and other countries and regions for the treatment of early and metastatic HER2-positive breast cancer patients.
-
J Clin Oncol: Prognosis for patients with recurrent high-risk neuroblastoma with I/T/DIN/GM-CSF
Time of Update: 2022-10-12
Progression-free survival in patients who achieved objective remission with I/T/DIN/GM-CSF therapyPatients were treated with a median course of 4.
Progression-free survival in patients who achieved objective remission with I/T/DIN/GM-CSF therapyPatients were treated with a median course of 4.
-
Prostate: Does metformin have an effect on mortality in Asian prostate cancer with diabetes who undergo androgen deprivation therapy?
Time of Update: 2022-10-12
Sep 2022 Globally, prostate cancer (PCa) was the second most common cancer and the fifth leading cause of cancer death among men in 2012.
Sep 2022 Globally, prostate cancer (PCa) was the second most common cancer and the fifth leading cause of cancer death among men in 2012.